Virtual
Beyond CRISPR
CRISPR supercharged gene editing. But after a decade of focus on that breakthrough, some scientists are back at the drawing board — and the race is on for the next big gene editing tool. What strategies are leading the pack and what role will CRISPR play as new tools emerge? Hear from experts at the cutting edge of the newest technologies.
Entering the virtual lab with Stanford’s James Zou
James Zou works with hundreds and hundreds of scientists — but the vast majority of them live inside of his computer. Zou leads the Stanford AI for Science Lab, where he’s creating virtual labs for autonomous ‘scientists’ to debate, test and refine ideas. Join us for a conversation about his AI scientists and the ways they could change the drug discovery process.
Alzheimer’s and the blood-brain barrier
There’s a new energy behind Alzheimer’s drugs. For the past few years, side effect struggles put a damper on Eli Lilly and Biogen’s treatments. But now, there’s an new wave of research on therapeutics that can move past the blood-brain barrier, and both large and small companies are inching back into the space. How promising is this approach and why might it prove more effective?
The intelligence layer: Preparing your organization for AI-driven science
The journey from laboratory breakthrough to clinical reality is often hindered by a silent obstacle: fragmented data. This "data tax" manifests as stalled timelines, duplicated efforts, and underutilized R&D assets across the enterprise. As drug discovery grows more complex, the ability to transform disconnected information into a strategic, reusable knowledge base becomes a critical competitive advantage.
This session explores how a semantic intelligence layer unifies proprietary research with public knowledge, creating a biology-aware foundation for the entire organization. We will discuss how this interconnected approach eliminates silos, ensures IP traceability, and prepares the R&D pipeline for the era of AI-driven science. Discover how to turn fragmented data into a scalable engine for faster, more informed decision-making.
From discovery to delivery: Getting medicines to the patients who need them
Commercialization of a drug is more complex than ever. Development decisions made early, from target product profiles to patient subgroups and evidence planning, increasingly determine whether a medicine ever reaches the people who need it. Join us to hear how integrating these perspectives into the strategy from the earliest stages of R&D leads to sharper portfolio choices, more resilient launches and ultimately greater impact for patients — and why designing for the patient journey must start far earlier than most realize.
in-Person only
Happy hour
CRISPR cures — with Aurora Therapeutics CEO Ed Kaye
Join Ed Kaye for an intimate conversation about custom CRISPR cures. What scientific advances made the work his company aims to do possible and what others do Aurora hope to push forward?
